OmniAb to Participate in Two Investor Conferences in March
OmniAb (NASDAQ: OABI) has announced its participation in two major investor conferences in March. The company will attend the TD Cowen 45th Annual Health Care Conference from March 3-5 at the Boston Marriott Copley Place, where management will deliver a corporate overview on March 4th at 2:30 p.m. Eastern time and conduct one-on-one investor meetings.
Additionally, OmniAb will participate in the 2025 Leerink Partners Global Healthcare Conference from March 9-12 at the W Hotel South Beach in Miami, with management scheduled for one-on-one investor meetings on March 12th.
OmniAb (NASDAQ: OABI) ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo. La società parteciperà al 45° Annual Health Care Conference di TD Cowen dal 3 al 5 marzo presso il Boston Marriott Copley Place, dove il management presenterà una panoramica aziendale il 4 marzo alle 14:30 ora orientale e terrà incontri individuali con gli investitori.
Inoltre, OmniAb parteciperà alla 2025 Leerink Partners Global Healthcare Conference dal 9 al 12 marzo presso il W Hotel South Beach di Miami, con incontri pianificati per il 12 marzo.
OmniAb (NASDAQ: OABI) ha anunciado su participación en dos importantes conferencias para inversores en marzo. La compañía asistirá a la 45ª Conferencia Anual de Salud de TD Cowen del 3 al 5 de marzo en el Boston Marriott Copley Place, donde la dirección ofrecerá una visión general de la empresa el 4 de marzo a las 2:30 p.m., hora del este, y realizará reuniones individuales con inversores.
Además, OmniAb participará en la Conferencia Global de Salud de 2025 de Leerink Partners del 9 al 12 de marzo en el W Hotel South Beach en Miami, con reuniones individuales programadas para el 12 de marzo.
OmniAb (NASDAQ: OABI)는 3월에 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 3월 3일부터 5일까지 보스턴 메리어트 코플리 플레이스에서 열리는 TD Cowen 제45회 연례 헬스케어 회의에 참석하며, 경영진은 3월 4일 동부 시간으로 오후 2:30에 기업 개요를 발표하고 투자자 1:1 회의를 진행할 예정입니다.
또한, OmniAb는 3월 9일부터 12일까지 마이애미 W 호텔 사우스 비치에서 개최되는 2025 Leerink Partners 글로벌 헬스케어 회의에 참여하며, 경영진은 3월 12일에 1:1 투자자 회의를 진행할 예정입니다.
OmniAb (NASDAQ: OABI) a annoncé sa participation à deux grandes conférences pour investisseurs en mars. La société assistera à la 45ème Conférence Annuelle de Santé de TD Cowen du 3 au 5 mars au Boston Marriott Copley Place, où la direction présentera un aperçu de l'entreprise le 4 mars à 14h30, heure de l'Est, et tiendra des réunions en tête-à-tête avec les investisseurs.
De plus, OmniAb participera à la Conférence Mondiale de Santé 2025 de Leerink Partners du 9 au 12 mars au W Hotel South Beach à Miami, avec des réunions individuelles prévues le 12 mars.
OmniAb (NASDAQ: OABI) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März angekündigt. Das Unternehmen wird an der 45. jährlichen Gesundheitskonferenz von TD Cowen vom 3. bis 5. März im Boston Marriott Copley Place teilnehmen, wo das Management am 4. März um 14:30 Uhr Eastern Time eine Unternehmensübersicht präsentieren und Einzelgespräche mit Investoren führen wird.
Darüber hinaus wird OmniAb an der 2025 Leerink Partners Global Healthcare Conference vom 9. bis 12. März im W Hotel South Beach in Miami teilnehmen, mit geplanten Einzelgesprächen mit Investoren am 12. März.
- None.
- None.
- TD Cowen 45th Annual Health Care Conference, March 3-5 at the Boston Marriott Copley Place. Management will be presenting a corporate overview on Tuesday, March 4th at 2:30 p.m. Eastern time and will be holding one-on-one meetings with investors.
-
2025 Leerink Partners Global Healthcare Conference, March 9-12 at the W Hotel South Beach in
Miami . Management will hold one-on-one meetings with investors on Wednesday, March 12th.
About OmniAb®
OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203086560/en/
OmniAb, Inc.
Neha Singh, Ph.D.
investors@OmniAb.com
X @OmniAbTech
(510) 768-7760
Source: OmniAb, Inc.
FAQ
When is OmniAb (OABI) presenting at the TD Cowen Healthcare Conference in March 2024?
Which investor conferences is OmniAb (OABI) attending in March 2024?
Where will the 2025 Leerink Partners Conference with OmniAb (OABI) be held?
What type of investor meetings is OmniAb (OABI) conducting at these March conferences?
